Hematology

Review top news and interview highlights from the week ending November 12, 2021.

The first in-human study of CAR macrophages has dosed 2 participants so far.

The associate professor of medicine from MD Anderson Cancer Center discussed data from the phase 1 cohort of liso-cel combined with ibrutinib.

Three patients dosed had tumors shrinkages of 18%, 21%, and 27%.

The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Data from the IMA203 trial were presented at the SITC 2021 annual meeting.

Sonny Hsiao, PhD, chief executive officer, president and cofounder, Acepodia, discussed the company’s future research and plans.

The director of Myeloma Immunotherapy at University of Pennsylvania discussed ciltacabtagene autoleucel's safety profile.

TCR² Therapeutics is collaborating with Bristol Myers Squibb to evaluate combination therapies in a phase 2 trial.

The hematologist and oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential utility of natural killer cells in multiple myeloma.

Primary efficacy data released by Sangamo Therapeutics showed that above normal α-Gal A activity was maintained for up to a year after treatment.

Yazeed Sawalha, MD, hematologist, Ohio State University Comprehensive Cancer Center, discussed how socioeconomic factors can affect use of ASCT in mantle cell lymphoma.

Autologous hematopoietic stem-cell transplantation maintained its long-term efficacy over interferon alfa in patients with mantle cell lymphoma.

The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s lead programs and future plans.

A new project is manufacturing a “purified” version of CAR-T-cells currently used to treat types of lymphoma and leukemia.

The professor from University of Texas MD Anderson Cancer Center discussed the real-world efficacy of the first CAR T therapy for the treatment of mantle cell lymphoma.

Review top news and interview highlights from the week ending November 5, 2021.

The hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.

Dipenkumar Modi, MD, discussed novel treatment options in leukemias and lymphomas.

The director at Dana-Farber Cancer Institute discussed future efforts to prevent the development of multiple myeloma.

The FDA also accepted a Type II Variation for the use of tisagenlecleucel in patients with R/R FL following 2 prior lines of treatment.

Paul Lammers, MD, MSc, president and chief executive officer, Triumvira Immunologics, discussed the challenges of manufacturing cell therapies.

The FDA has pushed cilta-cel's BLA PDUFA date back by almost 4 months.

The vaccination therapy improved progression-free survival by 3.1 months over standard care in 1 patient treated.

The hematologist/oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential of vaccine-based therapies in multiple myeloma.

Partners in the Bespoke Gene Therapy Consortium include the NIH, FDA, private companies such as Pfizer and Biogen, and non-profits.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s expansion into gene therapies.

Ide-cel's March 2021 FDA approval marks a significant advance in relapsed/refractory multiple myeloma treatment.

Rick Fair, president and chief executive officer, Bellicum Pharmaceuticals, discussed the company’s programs and future plans.

Doctors debated the roles of allogeneic hematopoietic stem cell transplant and CAR T-cell therapy for the treatment of aggressive B-cell lymphoma.